Literature DB >> 9892097

Brain tumor survival: results from the National Cancer Data Base.

T S Surawicz1, F Davis, S Freels, E R Laws, H R Menck.   

Abstract

Hospital-based data reported to the National Cancer Data Base (NCDB) were available for over 60,000 patients with a primary brain tumor diagnosed from 1985-1988 and 1990-1992. The most common histologies were glioblastomas, astrocytomas and meningiomas. Five-year survival rates for these tumors were 2%, 30% and 70% respectively. Histology, age at diagnosis, behavior, and location were important variables in estimating survival. Comparisons with population-based registry data suggest that the malignant tumors are well represented in NCDB, but the benign histologies are under-reported. Survival estimates for the malignant tumors are comparable to previously reported studies. The NCDB provides recent information on brain tumor distribution and survival patterns not available in other large databases.

Entities:  

Mesh:

Year:  1998        PMID: 9892097     DOI: 10.1023/a:1006091608586

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma.

Authors:  M J Winger; D R Macdonald; J G Cairncross
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

2.  The National Cancer Data Base and physician network.

Authors:  H R Menck; C Blankenship; A M Fremgen
Journal:  Top Health Inf Manage       Date:  1997-02

3.  An epidemiological study of brain tumours in the elderly.

Authors:  K Takeuchi; K Sano; K Nomura
Journal:  Neurol Res       Date:  1991-03       Impact factor: 2.448

4.  Descriptive epidemiology of malignant brain tumors in the Swiss Canton of Vaud.

Authors:  F Levi; C La Vecchia; V C Te
Journal:  Neuroepidemiology       Date:  1990       Impact factor: 3.282

5.  Patient age, histologic features, and length of survival in patients with glioblastoma multiforme.

Authors:  P C Burger; S B Green
Journal:  Cancer       Date:  1987-05-01       Impact factor: 6.860

6.  National survey of patterns of care for brain-tumor patients.

Authors:  M S Mahaley; C Mettlin; N Natarajan; E R Laws; B B Peace
Journal:  J Neurosurg       Date:  1989-12       Impact factor: 5.115

7.  A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984.

Authors:  M Kallio; R Sankila; J Jääskeläinen; S Karjalainen; T Hakulinen
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

8.  The glioblastoma multiforme in Georgia, 1977-1981.

Authors:  R E McLendon; J S Robinson; D B Chambers; S Grufferman; P C Burger
Journal:  Cancer       Date:  1985-08-15       Impact factor: 6.860

9.  Selection bias in clinical trials of anaplastic glioma.

Authors:  M J Winger; D R Macdonald; S C Schold; J G Cairncross
Journal:  Ann Neurol       Date:  1989-10       Impact factor: 10.422

10.  Incidence and survival of brain tumors: a population-based study.

Authors:  M Sant; P Crosignani; B M Bordo; G Nicola; M Bianchi; F Berrino
Journal:  Tumori       Date:  1988-06-30
View more
  100 in total

1.  Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model.

Authors:  Wentao Jia; Colleen Jackson-Cook; Martin R Graf
Journal:  J Neuroimmunol       Date:  2010-05-08       Impact factor: 3.478

Review 2.  Therapeutic window, a critical developmental stage for stem cell therapies.

Authors:  Shengwen Calvin Li; Yuan-Ping Han; Brent A Dethlefs; William G Loudon
Journal:  Curr Stem Cell Res Ther       Date:  2010-12       Impact factor: 3.828

3.  Direct DNA methylation profiling using methyl binding domain proteins.

Authors:  Yinni Yu; Steve Blair; David Gillespie; Randy Jensen; David Myszka; Ahmed H Badran; Indraneel Ghosh; Alexander Chagovetz
Journal:  Anal Chem       Date:  2010-06-15       Impact factor: 6.986

4.  New gene signatures for pediatric brain tumors: a step forward in the understanding of molecular basis of CNS PNET.

Authors:  Raúl Alelú-Paz; Santiago Ropero
Journal:  Transl Pediatr       Date:  2013-01

5.  Unequal Cumulative Incidence and Mortality Outcome in Childhood Brain and Central Nervous System Malignancy in the USA.

Authors:  L Holmes; P Chavan; T Blake; K Dabney
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-07

6.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

7.  Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma.

Authors:  Thierry Lesimple; Mohammed B Hassel; Daniel Gédouin; Eric Seigneuret; Béatrice Carsin; Abderrahmane Hamlat; Laurent Riffaud; Hélène Simon; Jean P Malhaire; Yvon Guégan
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

8.  An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.

Authors:  Xinmei Zhu; Chuanzhen Lu; Baoguo Xiao; Jian Qiao; Yi Sun
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

9.  The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction.

Authors:  Yan-Yan Yan; Jian-Ping Bai; Yong Xie; Jie-Zhong Yu; Cun-Gen Ma
Journal:  Oncol Lett       Date:  2012-10-22       Impact factor: 2.967

10.  Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma.

Authors:  Darnell T Josiah; Dongqin Zhu; Fernanda Dreher; John Olson; Grant McFadden; Hannah Caldas
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.